Background: A malfunction in the melanocortin-4 receptor (MC4R) is associated with obesity in rare genetic syndromes; setmelanotide is a new drug that activates this receptor and is being used to treat severe obesity. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.